Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: BAG5

Gene summary for BAG5

Gene summary.

Gene information	Species	Human
	Gene symbol	BAG5
	Gene ID	9529
	Gene name	BAG cochaperone 5
	Gene Alias	BAG-5
	Cytomap	14q32.33
	Gene Type	protein-coding
	GO ID	GO:0006457
	UniProtAcc	A0A024R6M6

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9529	BAG5	LZE4T	Human	Esophagus	ESCC	3.55e-09	2.53e-01	0.0811
9529	BAG5	LZE7T	Human	Esophagus	ESCC	1.89e-03	1.46e-01	0.0667
9529	BAG5	LZE8T	Human	Esophagus	ESCC	1.17e-05	1.71e-02	0.067
9529	BAG5	LZE20T	Human	Esophagus	ESCC	2.68e-07	8.45e-02	0.0662
9529	BAG5	LZE24T	Human	Esophagus	ESCC	3.03e-12	4.02e-01	0.0596
9529	BAG5	LZE6T	Human	Esophagus	ESCC	9.62e-03	2.86e-02	0.0845
9529	BAG5	P1T-E	Human	Esophagus	ESCC	3.28e-03	1.78e-01	0.0875
9529	BAG5	P2T-E	Human	Esophagus	ESCC	1.13e-20	2.58e-01	0.1177
9529	BAG5	P4T-E	Human	Esophagus	ESCC	9.09e-16	4.40e-01	0.1323
9529	BAG5	P5T-E	Human	Esophagus	ESCC	3.96e-15	3.15e-01	0.1327
9529	BAG5	P8T-E	Human	Esophagus	ESCC	8.37e-16	3.43e-01	0.0889
9529	BAG5	P9T-E	Human	Esophagus	ESCC	1.26e-04	1.13e-01	0.1131
9529	BAG5	P10T-E	Human	Esophagus	ESCC	3.29e-61	1.25e+00	0.116
9529	BAG5	P11T-E	Human	Esophagus	ESCC	2.49e-09	2.65e-01	0.1426
9529	BAG5	P12T-E	Human	Esophagus	ESCC	1.25e-26	6.40e-01	0.1122
9529	BAG5	P15T-E	Human	Esophagus	ESCC	2.58e-26	6.03e-01	0.1149
9529	BAG5	P16T-E	Human	Esophagus	ESCC	9.41e-15	2.95e-01	0.1153
9529	BAG5	P17T-E	Human	Esophagus	ESCC	6.47e-14	2.97e-01	0.1278
9529	BAG5	P20T-E	Human	Esophagus	ESCC	6.63e-14	2.10e-01	0.1124
9529	BAG5	P21T-E	Human	Esophagus	ESCC	6.63e-15	2.12e-01	0.1617

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:190332112	Liver	Cirrhotic	negative regulation of protein modification by small protein conjugation or removal	40/4634	95/18723	1.50e-04	1.44e-03	40
GO:19032017	Liver	Cirrhotic	regulation of oxidative stress-induced cell death	33/4634	74/18723	1.51e-04	1.45e-03	33
GO:005134812	Liver	Cirrhotic	negative regulation of transferase activity	93/4634	268/18723	1.55e-04	1.47e-03	93
GO:19021767	Liver	Cirrhotic	negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	13/4634	20/18723	1.63e-04	1.54e-03	13
GO:00420267	Liver	Cirrhotic	protein refolding	14/4634	23/18723	2.50e-04	2.26e-03	14
GO:200005912	Liver	Cirrhotic	negative regulation of ubiquitin-dependent protein catabolic process	23/4634	48/18723	4.19e-04	3.45e-03	23
GO:00708416	Liver	Cirrhotic	inclusion body assembly	14/4634	24/18723	4.64e-04	3.75e-03	14
GO:00900835	Liver	Cirrhotic	regulation of inclusion body assembly	11/4634	17/18723	5.66e-04	4.44e-03	11
GO:19004077	Liver	Cirrhotic	regulation of cellular response to oxidative stress	36/4634	89/18723	7.79e-04	5.73e-03	36
GO:190336311	Liver	Cirrhotic	negative regulation of cellular protein catabolic process	31/4634	75/18723	1.15e-03	7.84e-03	31
GO:1903332	Liver	Cirrhotic	regulation of protein folding	8/4634	12/18723	2.59e-03	1.53e-02	8
GO:190305111	Liver	Cirrhotic	negative regulation of proteolysis involved in cellular protein catabolic process	26/4634	64/18723	3.69e-03	2.03e-02	26
GO:005143812	Liver	Cirrhotic	regulation of ubiquitin-protein transferase activity	22/4634	53/18723	5.36e-03	2.73e-02	22
GO:19032027	Liver	Cirrhotic	negative regulation of oxidative stress-induced cell death	22/4634	53/18723	5.36e-03	2.73e-02	22
GO:19028827	Liver	Cirrhotic	regulation of response to oxidative stress	36/4634	98/18723	5.44e-03	2.77e-02	36
GO:003243511	Liver	Cirrhotic	negative regulation of proteasomal ubiquitin-dependent protein catabolic process	16/4634	35/18723	5.53e-03	2.80e-02	16
GO:005144412	Liver	Cirrhotic	negative regulation of ubiquitin-protein transferase activity	10/4634	19/18723	8.23e-03	3.83e-02	10
GO:001049822	Liver	HCC	proteasomal protein catabolic process	351/7958	490/18723	6.92e-40	1.46e-36	351
GO:004316122	Liver	HCC	proteasome-mediated ubiquitin-dependent protein catabolic process	299/7958	412/18723	7.82e-36	8.27e-33	299
GO:004217622	Liver	HCC	regulation of protein catabolic process	267/7958	391/18723	2.45e-25	7.38e-23	267

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

BAG5

SNV

Missense_Mutation

c.349N>C

p.Glu117Gln

p.E117Q

Q9UL15

protein_coding

tolerated(0.48)

probably_damaging(0.951)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

BAG5

SNV

Missense_Mutation

novel

c.574N>T

p.His192Tyr

p.H192Y

Q9UL15

protein_coding

deleterious_low_confidence(0)

benign(0.003)

TCGA-PE-A5DE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

BAG5

SNV

Missense_Mutation

novel

c.977N>T

p.Arg326Ile

p.R326I

Q9UL15

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.667)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

BAG5

SNV

Missense_Mutation

c.981N>A

p.Met327Ile

p.M327I

Q9UL15

protein_coding

tolerated_low_confidence(0.12)

benign(0.083)

TCGA-JW-A5VL-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

BAG5

SNV

Missense_Mutation

novel

c.1057N>A

p.Gly353Ser

p.G353S

Q9UL15

protein_coding

tolerated(0.19)

benign(0.009)

TCGA-JX-A3Q0-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

BAG5

SNV

Missense_Mutation

c.981N>C

p.Met327Ile

p.M327I

Q9UL15

protein_coding

tolerated_low_confidence(0.12)

benign(0.083)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

BAG5

SNV

Missense_Mutation

c.81N>C

p.Trp27Cys

p.W27C

Q9UL15

protein_coding

deleterious_low_confidence(0)

benign(0.023)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

BAG5

SNV

Missense_Mutation

novel

c.1431N>G

p.Ser477Arg

p.S477R

Q9UL15

protein_coding

tolerated(0.07)

possibly_damaging(0.734)

TCGA-VS-A94Z-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

BAG5

insertion

Frame_Shift_Ins

novel

c.260_261insCT

p.Thr88Ter

p.T88*

Q9UL15

protein_coding

TCGA-LP-A7HU-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

BAG5

SNV

Missense_Mutation

c.1438N>A

p.Asp480Asn

p.D480N

Q9UL15

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-AG-3892-01

Colorectum

rectum adenocarcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1